The U.S. Supreme Court has reinstated broad access to the abortion pill mifepristone, blocking a lower court ruling that threatened to disrupt a primary method of abortion nationwide.

Supreme Court Ruling

The order, signed by Justice Samuel Alito, temporarily allows women seeking to terminate their pregnancies to obtain the pill through pharmacies or mail without an in-person doctor visit. This practice had been in place for several years before recent restrictions were imposed by a federal appeals court.

Legal Battles and Background

This ruling comes as legal battles over abortion access continue following the 2022 overturning of Roe v. Wade. The 2022 decision ended the constitutional right to abortion, leading to varied state laws regarding abortion access.

State Responses and Telehealth

Some Democrat-led states have enacted laws to protect providers prescribing abortion medication remotely, mitigating the impact of bans in Republican-led states. A recent report indicated that in states with total abortion bans, more women accessed abortions via telehealth prescriptions last year than by traveling to other states.

The Louisiana Lawsuit

Louisiana filed a lawsuit challenging the Food and Drug Administration’s (FDA) regulations regarding mifepristone prescriptions, arguing they undermine the state’s existing abortion ban. The case also questioned the drug’s safety, despite the FDA repeatedly affirming its safety and effectiveness over 25 years.

Mifepristone and Misoprostol

Mifepristone is typically used with misoprostol to terminate pregnancies, achieving a 97.4% success rate according to the FDA. Misoprostol can also be used alone, with effectiveness rates around 80% or higher. Unlike mifepristone, misoprostol is FDA-approved for treating stomach ulcers, and has faced less scrutiny from abortion opponents.

Impact on Providers and Patients

Some organizations prescribing abortion pills remotely switched to using only misoprostol over the weekend due to the uncertainty. However, Dr. Angel Foster, founder of The Massachusetts Abortion Access Project, stated her organization was able to return to the two-drug combination following the Supreme Court’s decision.

“Regardless of what happens with this regulatory issue, we and other groups will continue to provide high-quality abortion care to patients in all 50 states,” Foster said.

Providers are now asking patients to approve shipments of pills with or without mifepristone, preparing for potential future restrictions. Julie Burkhart, founder of Wellspring Health Access, emphasized the importance of the temporary stay, stating, “We have a little more time to navigate this new landscape with the stay.” Elizabeth Ling of If/When/How clarified that accessing care will not become illegal regardless of the legal outcome.